As the Democratic Republic of the Congo grapples with the fastest-growing Ebola outbreak on record, GeoVax Labs, Inc. (Nasdaq: GOVX) has highlighted its potential to contribute to the global response. The outbreak, caused by the Bundibugyo virus (BDBV), has already resulted in over 4,300 cases and 2,000 deaths, according to the World Health Organization (WHO). The trajectory of this outbreak could surpass the death toll of the 2014-2016 West Africa Ebola epidemic, which claimed more than 11,000 lives. Currently, there is no approved vaccine specifically targeting Bundibugyo virus.
GeoVax, a biotechnology company developing vaccines and immunotherapies, has extensive experience in developing vaccines against high-consequence hemorrhagic fever viruses using its Modified Vaccinia Ankara (MVA) platform. The company's portfolio includes vaccine candidates targeting Zaire ebolavirus, Sudan ebolavirus, and Marburg virus. These candidates have undergone rigorous preclinical development, including non-human primate lethal-challenge studies that demonstrated encouraging protective efficacy.
David Dodd, Chairman and Chief Executive Officer of GeoVax, emphasized the importance of having vaccine technologies ready before a crisis. "The rapidly escalating Ebola Bundibugyo outbreak underscores the importance of having vaccine technologies and capabilities available before a crisis occurs," he said. "We are prepared to engage with WHO, Africa CDC, national public health authorities, and other appropriate organizations to determine whether our vaccine candidates, technology, or scientific expertise could contribute to the response. Where appropriate, we are also willing to make relevant vaccine materials available for evaluation against Bundibugyo virus."
GeoVax's lead infectious disease priority remains GEO-MVA, its MVA-based vaccine being developed as an additional source of MVA vaccine capacity for prevention of mpox and smallpox. The company is preparing to initiate a pivotal clinical development program based on an immunobridging accelerated regulatory pathway. Portions of this program are expected to be conducted in African regions confronting significant infectious disease challenges, including areas affected by the current Bundibugyo Ebola outbreak.
As part of preparations for the GEO-MVA clinical program, GeoVax is engaging with healthcare, research, and public health organizations in the region, including entities involved in responding to the Ebola outbreak. These relationships provide a natural opportunity to explore whether GeoVax's scientific expertise, MVA platform capabilities, and existing hemorrhagic fever vaccine candidates could appropriately contribute to the broader public health response.
"Our relationships in the region are being developed first and foremost to advance GEO-MVA, but many of the organizations with whom we are engaging are simultaneously confronting this Ebola outbreak," Dodd continued. "Given our experience, we believe it is appropriate to ask how we might help. Any such effort would be pursued collaboratively while maintaining our operational and capital focus on GEO-MVA."
In parallel with GEO-MVA, GeoVax retains a portfolio of MVA-based hemorrhagic fever vaccine candidates that have demonstrated protective efficacy in animal challenge models, including non-human primate studies. These programs represent potential strategic optionality beyond GEO-MVA. The company is open to discussing collaborations, licensing arrangements, public-private partnerships, and other strategic structures that could provide resources and expertise for further evaluation and development of these assets without diverting primary resources from GEO-MVA.
GeoVax believes its combination of MVA platform expertise, hemorrhagic fever vaccine candidates, and work to advance scalable MVA manufacturing provides a foundation for potential collaborations addressing Ebola and other emerging infectious disease threats. The company's efforts align with the urgent need for vaccine solutions as the current outbreak continues to spread.
